Your Health, We Care
Unresectable or Metastatic MelanomaCobimetinib® is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma harboring BRAF V600E or V600K mutations.
Histiocytic NeoplasmsCobimetinib® is indicated as monotherapy for the treatment of adult patients with histiocytic neoplasms.
FDA，2023.05
This product is indicated for the treatment of adult patients with unresectable ···【more】
Release date：2026-01-05Recommended：9
